AJU IB Investment

Aju IB Investment is a venture capital firm that offers SMEs with investments and consulting services. Aju IB Investment offers consulting services that focus on business management, tax, accounting, legal, mergers and acquisitions, additional funding, marketing, and technology support. Aju IB Investment was founded in September 1974 and is based in Seoul, South Korea.

Daeseok Jung

Director, Investment Strategy Division

Yoon M.B.A., Derek

Partner

77 past transactions

ICT Compliance

Seed Round in 2022
ICT Compliance is a tech company specializing in authentication solutions.

ENCell

Series C in 2022
ENCell is a biotech company that develops and manufactures biopharmaceuticals.

Mxt Biotech

Series A in 2022
Mxt Biotech is a biotechnology company that develops transformative microfluidic platforms for cell engineering and immunotherapies.

Live Anywhere

Seed Round in 2022
Live Anywhere is NO.1 short-term rental platform. You can rent over 10K fully furnished houses in 165 cities over the world.

Fine One

Seed Round in 2022
Fine One is an OLED evaporator parts developer company that supplies display semi core process equipment parts for the industry.

DAAN Biotherapeutics

Seed Round in 2022
DAAN Biotherapeutics develops novel treatments for cancer patients. The company conducts cancer treatment research and development, including cell therapies, antibodies, and small molecule inhibitors.

Value Link Oil

Series A in 2022
Value Link Oil is a platform service company that provides transportation connection, data-based management, and consulting services.

iN Therapeutics

Series B in 2022
iN Therapeutics is a biotechnology platform that develops new drugs for patients suffering from incurable neurological diseases.

Willog Co., Ltd.

Series A in 2022
Willog is an IoT-based logistics intelligence company that provides real-time visibility across the entire supply chain through its proprietary sensor devices and platform. This enables businesses to monitor various data points such as location, temperature, humidity, and shock during transportation, helping them track assets and ensure consistent product quality. Willog’s solution helps identify potential issues in the logistics process in advance and suggests solutions to save time and reduce costs. It is applicable across various industries and empowers customers to make data-driven decisions. • Sensor Devices (Hardware) To meet the needs of various customers and transportation sectors, Willog offers a lineup of monitoring devices tailored to each logistics segment. These devices collect logistics data throughout the transport process and securely transmit it to the monitoring software. • Monitoring Solution (Software) Willog provides software optimized for logistics processes in tandem with its sensor devices. The software intuitively displays logistics condition data such as temperature, humidity, shock, and light levels collected during transport, eliminating the need for time-consuming manual tasks like post-delivery data mapping. Based on the collected data, the system analyzes shipment history to detect potential issues in advance during transportation and storage, helping to predict and minimize loss or cost. Additionally, Willog’s proprietary data analysis methodology, Willog Connected Intelligence, generates specialized analytics reports for each logistics domain—delivering insights beyond basic data logs and alerts.

Organoid Sciences

Series B in 2022
Organoid Sciences is an organoid-based treatment drug development company that offers drug screening and regenerative medicines.

Victex

Venture Round in 2021
Victex is a dry ice washer manufacturing company.

Happy Moonday

Series A in 2021
Happy Moonday makes organic sanitary napkins and tampons for women's health.

Astron Security

Series A in 2021
Astron Security is a cloud security technology company that provides core technology services for businesses.

Onuii

Series A in 2021
Onuii helps students receive study methods, entrance exams, and career counselling from tutors. It is a mathematical problem-solving application for middle and high school students.

Dot Mill

Seed Round in 2021
Dot Mill is a mixed reality content production company.

CORELINESOFT

Series C in 2021
CORELINESOFT develops medical software products.

SodaGift

Venture Round in 2021
SodaGift is an international gifting service firm. It focuses on a seamless user experience and multilingual customers.

S-Alpha Therapeutics

Series A in 2021
S-Alpha Therapeutics develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology. Company has developed several digital therapeutic products in its R&D pipeline.

Wavebridge

Series A in 2021
Wavebridge is a top-tier institutional digital asset company with expertise in both traditional and crypto finance. The company was established in November 2018 to provide a comprehensive suite of investment solutions utilizing its data processing and AI technology.

Reebonz Korea

Series A in 2021
Reebonz Korea operates as an online shopping site that offers various luxury brands' products and accessories.

PeopleBio

Post in 2021
PeopleBio develops diagnosis detection products and specializes in developing diagnostics for protein misfolding diseases.

GI Innovation

Series C in 2021
GI Innovation is a South Korean bio-venture company, integrating basic science and translational innovation in developing biologics for patients around the world. GI Innovation’s strategic focus is on immuno-oncology and inflammation/immunology diseases. GI Innovation has established GI-SMART platform technology that is designed to accelerate the development of biologics through the efficient optimization of multi-targeting fusion protein therapeutics with high quality and high productivity.

MEZOO

Series A in 2021
MEZOO is a medical device manufacturing company.

Gencurix

Venture Round in 2021
Gencurix develops various diagnostic products to support precision medicine.

iN Therapeutics

Series A in 2021
iN Therapeutics is a biotechnology platform that develops new drugs for patients suffering from incurable neurological diseases.

PEOPLE & TECHNOLOGY

Series A in 2021
PEOPLE AND TECHNOLOGY provides DX-based AI solutions on INDOOR GEOLOCATION AND SMART SENSING through its INDOORPLUS+ IoT, Location Based System (LBS) and Real Time Location System (RTLS) platform in the fields of healthcare, manufacturing, defense, smart cities, and the public sector. More than 100 corporate customers in various business sectors such as healthcare, banking, manufacturing, retail, energy and public services have already chosen PEOPLE AND TECHNOLOGY to deploy industry grade solutions for employee safety, asset tracking & monitoring, security & access control, flow management and process efficiency. They have gained improvements in productivity and process efficiency while reducing their corporate risks and optimizing their procurement. Since its foundation in 2013, PEOPLE AND TECHNOLOGY has become a leading provider in South Korea and is expanding overseas.

Cenyx Biotech

Series A in 2021
Cenyx Biotech develops diagnostic and therapeutic nano-compounds formed based on nanozymes and nanoparticles.

Biobab AiBIO

Series A in 2021
Biobab AiBIO is a biotechnology company that develops drugs utilize artificial intelligence.

MBD

Series B in 2021
MBD is a biotechnology company that specializes in 3D cell culture platforms.

S-Alpha Therapeutics

Seed Round in 2020
S-Alpha Therapeutics develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology. Company has developed several digital therapeutic products in its R&D pipeline.
OliX is a clinical stage biotechnology company, based on their own proprietary RNA interference (RNAi) technology regulating the expression of disease-causing genes.

CORELINESOFT

Series B in 2020
CORELINESOFT develops medical software products.

Trenbe

Series B in 2020
Trenbe is an e-commerce company of footwear products.

5minlab

Series A in 2020
'A game development company with superior techniques leading to business growth' 5minlab is a PC/mobile game development company based in Seoul, South Korea. Since our launch in 2013, we’ve brought 5 PC/mobile games, 3 VR games, and 24 hyper-casual games to the global market. In addition, our technical skills have developed over the years while performing various outsourcing tasks and projects. Since 2018, based on our years' worth of know-how, a PvP game 'Smash Legends' has started developing, which allowed users to participate and gather worldwide. In 2020, 5minlab successfully attracted Series A investment from 4 investors due to the success of the game in 2019. Currently, 5minLab has 70 experts from various backgrounds, from a brilliant developer born in 00 to the art director of ‘Dragon Nest' and ‘Phantom Chaser'. The senior development leader of ‘Dungeon & Fighter'. Starting with 'Smash Legends', which is scheduled to be released in the first half of 2021, 5minlab aims to release the next game in 2024 to become a developer that can create global IP in a chain.

Laundrygo

Series B in 2020
Laundrygo is a on-demand laundry service.

kukka

Series A in 2020
kukka is a provider of flower subscription services.

Organoid Sciences

Series A in 2020
Organoid Sciences is an organoid-based treatment drug development company that offers drug screening and regenerative medicines.

Macaron M

Series A in 2020
Macaron M is a mobile application that offers taxi services.

Seer

Series D in 2019
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

SparkPlus

Series B in 2019
SparkPlus operates a coworking space. It was designed for businesses that were having trouble with their offices. It solves all corporate office problems quickly and easily. Its goal is to allow clients to concentrate on their day job.

FamePick

Series A in 2019
FamePick provides seasoned, business-savvy creators with the assistance they require so that they may control their story and preserve the integrity of their brand. They offer special tools designed specifically with established creators in mind to assist them in locating partners that share their beliefs, building stronger relationships, diversifying into other platforms and paid media, and determining their market value.

Fresh Easy

Series C in 2019
Fresh Easy is a distributor of meal kits.

Raonsecure

Venture Round in 2019
Raonsecure is pursuing and holds a number of security technology patents in the IoT / integrated security space. They promote future-oriented technology and products for integrated authentication by combining the next-generation of authentication technology including human/device authentication, security-applied technology, and FIDO (Fast IDentity Online) based on PKI technology.

Seer

Series C in 2019
Seer is a developer of a life sciences and health data platform intended to facilitate early, pre-symptomatic detection of chronic life-threatening diseases. The company's platform captures and translates molecular insights from the proteome with improved accuracy and speed, enabling healthcare professionals to detect cancer and neurological diseases, drive earlier treatment and improve patient outcomes.

Trefoil Therapeutics

Series A in 2019
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Tibit Communications

Series B in 2019
TiBiT Communications offers a disruptive technology that will fundamentally change the way broadband access is deployed in the Service Provider markets worldwide (Cable MSO, Telco and Wireless). They make small, low powered solutions that can be easily placed anywhere in the network to enable multi-Gigabit connectivity for low end cost effective switching equipment in a Software Defined Network.

Innopharmascreen

Series A in 2019
Innopharmascreen develops a protein chip-based, AI-aided drug discovery platform built to find novel drugs for a selected target. The company focuses on assisting in novel drug discovery through its technology, which is based on a protein-protein interaction assay system and an antibody microarray-based mode of action, helping pharmaceutical and biotechnology companies discover new drugs.

Woogene B&G

Venture Round in 2019
Woogene B&G is a high-tech industry, specializing in biotechnology and biological industry.

bHaptics

Series A in 2019
We bring haptics to your life from Head to Toe with our Full-Body haptic devices! bHaptics brings a ‘sense of touch’ to virtual reality more closely than ever before imaginable. A high-end haptic vest with 40 feedback points. It offers a lag-free wireless connection and a variety of games with native support. The vest is also compatible with any types of platforms, allowing users to experience audio-based haptics when listening to music, watching movies, or playing games without native support. Please come and feel all the vives with us!

Kymera Therapeutics

Series B in 2018
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.

Vendys

Series B in 2018
Vendys offers mobile meal management solution for office workers.

Newploy

Series B in 2018
Newploy is a payroll work automation platform that Automate payroll tasks through robotic process automation (RPA) technology.

Albam

Series A in 2018
Albam : A mobile based HR Solution that is available for both Managers(Admins) and Staffs in App both IOS & Android. The average HR manager spends 45 minutes a day to calculate time attendance & payroll. With Albam, time is reduced by 70% to only 15 minutes. Albam help enterprises in simplifying and automating their time attendance system to payroll solution. Our easy to use and simple Cloud based Human Resource solution helps companies in reducing the high costs that are often associated in the investment of Time Attendance system which includes the purchase of expensive fingerprint machines and training of IT Personnels. With Albam, employees can clock in and clock out directly right away from their smartphone, clock in and clock out has never been this easier with Albam.

Triple

Series A in 2018
Triple is a travel data services startup.

Watcha

Series C in 2018
WATCHA - Launched in AUG 2012, it quickly became Korea’s favorite movie review app - Its core competency lies in personalized recommendation technology - once users rate movie, WATCHA predicts how they will like movies they haven’t yet seen - Now provides the widest and most accurate movie, TV show and book reviews - Launched in Japan in 2015 WATCHA PLAY - Launched in JAN 2016 - Subscription VOD service for movie and TV series available on multiple devices including Web, iOS/Android mobile and tablet, Samsung/LG Smart TV, Google Chromecast, Android TV - Provides extremely accurate personalized content recommendation, powered by WATCHA - 75% of content consumed based on recommendations Comment by Apple, App Store Editor Team “Thanks to its large volume of reliable review data collected from users, WATCHA PLAY can recommend contents that perfectly satisfy my taste. Please don’t waste your time in choosing what to watch. Trust WATCHA PLAY and Enjoy tonight”

Tryus & Company

Series A in 2018
Tryus & Company is a food ingredient search app.

Channel Talk

Series B in 2017
Channel Talk is an AI messenger that is focused on helping DTC companies provide VIP-level customer service. We raised $40 million USD in our Series C, and are one of the fastest-growing B2B SaaS startups, currently servicing more than 150,000 brands across the world. At Channel Talk, we believe that a good product nurtures growth in a business and that simple conversations with customers can become the driving force for success. We help you stand out by utilizing AI to resolve repetitive inquiries so you have time to build genuine relationships through our powerful CRM and provide excellent support to your customers.

Kezar Life Sciences

Series B in 2017
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

Plexense

Venture Round in 2017
Plexense is a developer of immunoassay for clinical, agricultural and biological testing.

Yanolja

Private Equity Round in 2017
Yanolja is a leisure platform that provides online accommodation and travel services. Its platform offers information regarding all aspects of travel including accommodation, leisure, and transportation that allow clients to book every type of hotel room from overseas. The company was founded in 2005 and is headquartered in Seoul, South Korea.

Blind

Series B in 2017
Blind is a trusted community where verified professionals connect to discuss what matters most. Professionals anonymously communicate in private company channels and openly with users across industries. Blind is a place where 4.1M+ professionals worldwide share advice, provide honest perspectives, discuss company culture and discover relevant career information. Blind is a platform for change. Our mission towards transparency breaks down professional barriers, empowering informed decisions and inspiring productive change in the workplace.

Trefoil Therapeutics

Series A in 2017
Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

Honey Biz

Series B in 2016
Honey Biz is a mobile app that provides food delivery services.

Apellis Pharmaceuticals

Series D in 2016
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.

Dano

Series A in 2016
Dano (다노) is a Korea-based company that develops diet apps for the health and fitness sector. Dano’s Diet App is a journal-based app that enables users to stay focused and monitor their daily progress. The app offers many useful tools to help users stay committed to their diet programs. Dano also released Diet Cover, a lock-screen photo app that enables users to have a photo of their role model, in order to remind themselves about their diet during the course of the day. This app enables users to eat healthily and be mindful of their diet at any given moment. Dano was established in July 2013.

Clearside Biomedical

Series C in 2015
Clearside BioMedical, an ophthalmic company, specializes in the research, development, and commercialization of therapeutic products through an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The company’s CLS1001 is under development for retinal applications through the delivery of therapeutics to the suprachoroidal space. Clearside BioMedical was incorporated in 2011 and is based in Atlanta, Georgia.

12cm

Series A in 2015
12cm operates echoss, a cloud O2O service platform that provides offline to mobile connection services. The company also offers echoss stamp products. 12cm’s platform also includes a service mobile plugin, commerce service, and coupon service components. In addition, its echoss platform is applied and extended to O2O service, including membership, promotion, mobile certification, commerce, and utility. It is based in Bundangdong, Kyonggi-do.

DRAMA & COMPANY

Series B in 2015
Draman Company is a Mobile-based startup offering a cloud-based business card management application. The company was established in June 2013.

Remember

Venture Round in 2015
Remember is the number one business card management application in Korea that secretary inputs directly when you take a business card.

Kezar Life Sciences

Series A in 2015
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

Apellis Pharmaceuticals

Series C in 2014
Apellis Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease. The company is leveraging courageous science, creativity, and compassion to deliver life-changing medicines. They aim to develop best-in-class and first-in-class therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology. It was founded in 2008 and headquartered in Waltham, Massachusetts, United States.

Aileron Therapeutics

Series E in 2014
Aileron Therapeutics is a biopharmaceutical company that develops a class of drugs called Stapled Peptides. Stapled Peptides represent the first general solution for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell.

Molecular Templates

Series C in 2014
Molecular Templates is a clinical-stage biopharmaceutical company developing therapeutic compounds for cancer and other serious diseases. It primarily develops a pipeline of therapies through its proprietary biologic-engineered toxin body (ETB) drug platform with unique mechanisms of action which are highly differentiated from antibody-drug conjugates (ADCs).

Bellicum Pharmaceuticals

Series C in 2014
Bellicum Pharmaceuticals is a clinical stage company developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response.

Amicogen

Post in 2013
Amicogen develops bioproducts and health functional food ingredients. Their products include endo-lac, ginseng extraction powder, cauliflower mushrooms, chitosan oligosaccharides, chitoslim, keyclean, and more.

Krafton

Venture Round in 2009
Krafton is a game developer for PC and mobile devices that focuses on fantasy games. Its vision is to stay a household name in video game development by keeping true to its core value of craftmanship.

Fangtek

Series C in 2006
Fangtek Electronics is an integrated circuit design company specialized in the design, development, and marketing of analog and mixed signals. The company’s products are mainly used in the field of communications, computers, and consumer electronics. As a high value-added integrated circuit supplier, Fangtek Electronics has been devoted to developing innovative solutions for power management. Through the accumulation of power device techniques and professional technologies of mixed signal design, Fangtek Electronics provides high-performance and low-cost audio power amplifiers, LED drivers, power management devices, and other products, which are widely used in the fields of voice, light, and electricity.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.